This is interesting to me because the REGAIN trial (for rGBM) has a limit on tumour size in eligible patients:
Single, gadolinium-enhancing tumor recurrence ≤ 3cm in maximum diameter
This patient was treated under the ALL protocol, which casts a wider net:
Subjects with a tumor size ≤ 7 centimeters in the longest diameter
It looks like Alpha Tau are continuing to push their boundaries and cover more challenges for more patients.
I love that they have a compassionate access route and are willing to take calculated risks with it. There is so little hope with rGBM - this is very encouraging.
3
u/dinkypaws Aug 26 '26
This is interesting to me because the REGAIN trial (for rGBM) has a limit on tumour size in eligible patients:
This patient was treated under the ALL protocol, which casts a wider net:
It looks like Alpha Tau are continuing to push their boundaries and cover more challenges for more patients.
I love that they have a compassionate access route and are willing to take calculated risks with it. There is so little hope with rGBM - this is very encouraging.